Cornerstone Capital Inc. Grows Stake in Pfizer Inc. $PFE

Cornerstone Capital Inc. raised its holdings in Pfizer Inc. (NYSE:PFE) by 258.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 267,909 shares of the biopharmaceutical company’s stock after buying an additional 193,179 shares during the quarter. Cornerstone Capital Inc.’s holdings in Pfizer were worth $6,451,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. State Street Corp raised its holdings in Pfizer by 0.5% in the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Pfizer by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock worth $3,235,642,000 after purchasing an additional 1,184,728 shares during the period. Morgan Stanley boosted its stake in shares of Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Pfizer during the 4th quarter valued at about $1,830,986,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PFE has been the subject of several research analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Pfizer in a report on Monday, August 3rd. Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Citigroup increased their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. Finally, Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.28.

Pfizer Trading Up 0.3%

Shares of NYSE PFE opened at $26.88 on Tuesday. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75. The stock has a market cap of $153.21 billion, a P/E ratio of 35.37 and a beta of 0.34. The firm has a 50-day moving average of $25.15 and a 200 day moving average of $26.20. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the prior year, the company earned $0.78 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.